ESMO 2019 | Long-term outcomes of nivo vs. nivo/ipi in melanoma brain metastases: ABC trial data

Georgina Long, MD, PhD, FRACP, University of Sydney, Sydney, Australia, discusses the long-term outcomes from the phase II ABC study of nivolumab vs. nivolumab and ipilimumab in patients with melanoma brain metastases (NCT02374242). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.